EGFR and neoplasm: This potential tumor-promoting activity was also supported by higher relative variant frequencies (RAFs) of ERBB2ΔEx16 detected in untreated LC patients than in their EGFR TKI-resistant counterparts or in GC patients (Figure 2B).